Current Neuropharmacology, 2023 · DOI: 10.2174/1570159X20666220830115018 · Published: January 1, 2023
Intracerebral hemorrhage (ICH) is a severe neurological condition with high rates of mortality and disability. Recent research indicates that white matter injury (WMI) significantly contributes to motor dysfunction following ICH. Neuroinflammation, mediated by microglia and astrocytes, plays a crucial role in the secondary WMI that occurs after ICH. The NLRP3 inflammasome exacerbates neuroinflammation and brain injury post-ICH. It is activated in both microglia and astrocytes, playing a significant role in neuroinflammation. Inhibiting NLRP3 inflammasome may reduce WMI by shifting microglia and astrocytes to an anti-inflammatory state after ICH. This review explores how neuroinflammation, influenced by the NLRP3 inflammasome, worsens secondary WMI after ICH and discusses potential therapeutic targets. Targeting the NLRP3 inflammasome could offer new strategies for treating WMI and promoting white matter repair in ICH patients.
NLRP3 inflammasome may be a key therapeutic target to mitigate secondary WMI after ICH by modulating microglia and astrocyte polarization.
Development of drugs targeting NLRP3 inflammasome could offer new treatment strategies to reduce WMI and promote WM repair in ICH.
Early suppression of NLRP3 inflammasome may protect secondary WMI and promote WM repair, improving neurological outcomes after ICH.